Compare Oatly Group AB - ADR (OTLY) vs 10X Genomics Inc (TXG) Price & Performance

Oatly (OTLY) trades at $13.52, down 3.98% today, with a bullish technical signal from a recent golden cross but bearish moving averages. Revenue growth improved to $862.46M in 2025, yet net losses persist at -$152.77M. The company raised its 2026 revenue outlook after Q2 results, driving positive sentiment from news outlets like Seeking Alpha on July 22, 2026.

Outlook hinges on margin expansion and path to profitability, with risks from high debt and cash burn. Analysts are mixed (44% buy, 50% hold), reflecting optimism on operational turnaround but caution on financial sustainability. Key catalysts include product innovation and market expansion, though negative cash flows and equity erosion pose significant investor risks.

TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.

Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.